Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years

BACKGROUND: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood. METHODS: We conducted a single-centre retrospective study and assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Kanai, Osamu, Hata, Hiroaki, Ishigami, Kenjiro, Nanba, Kazutaka, Esaka, Naoki, Seta, Koichi, Mio, Tadashi, Odagaki, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985534/
https://www.ncbi.nlm.nih.gov/pubmed/36919008
http://dx.doi.org/10.1016/j.ahr.2023.100130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985534/
https://www.ncbi.nlm.nih.gov/pubmed/36919008
http://dx.doi.org/10.1016/j.ahr.2023.100130

Ejemplares similares